Navigation Links
FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets
Date:10/13/2009

Four Companies Required to Stop Making and Distributing Illegal Opioid Pain Relievers

SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned four companies that they must stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics, commonly called narcotics, that are widely used to treat pain.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

These particular products have not received FDA approval and the agency has no evidence that they are safe and effective. Another manufacturer, Roxane Laboratories, markets FDA-approved codeine sulfate tablets and is able to meet the demand for the drug. The FDA does not anticipate a supply problem for codeine sulfate tablets.

"Consumers deserve and expect that their drugs meet modern FDA standards for safety, effectiveness, labeling, and quality. Removing unapproved products that do not meet those standards is an FDA priority," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research (CDER). "The FDA urges drug companies to ensure all drugs they make and market have appropriate FDA approval."

The names of the products and the manufacturers and distributors that received the warning letters are:

  • Codeine Sulfate Tablets, 30 mg, 60 mg - Lehigh Valley Technologies Inc., Allentown, Penn.
  • Codeine Sulfate Tablets, 30 mg, 60 mg - Cerovene Inc., Valley Cottage, N.Y.
  • Codeine Sulfate Tablets, 30 mg - Dava International Inc., Fort Lee, N.J.
  • Codeine Sulfate Tablets, 30 mg, 60 mg - Glenmark Generics Inc. USA, Mahwah, N.J.

Companies receiving the warning letters have 15 days to give the FDA a plan to discontinue marketing the unapproved drugs. Manufacturers have 90 days to cease manufacturing of new product, and distributors have 180 days to cease further shipment of existing products. Previously manufactured unapproved products may still be found on pharmacy shelves for a period of time.

Today's action is part of the FDA's initiative against the marketing of unapproved drugs, announced in June 2006. At that time, the agency published a Compliance Policy Guide describing the FDA's risk-based enforcement approach to unapproved products.

"Doctors and patients often find that some drugs on the market do not have FDA approval," said Deborah M. Autor, director of CDER's Office of Compliance. "This lack of approval undermines the FDA's process to ensure that safe and effective drugs are available to the U.S. public."

Consumers who rely on opioid analgesics for pain relief have access to products that have been evaluated by the FDA and determined to be safe and effective for use. There are other FDA-approved drugs, including different opioid analgesics, which can be used to relieve pain. Consumers should consult a health care professional for detailed guidance on treatment options.

For additional information, including copies of the warning letters that identify the firms involved and the names of their products, see the FDA's Unapproved Drugs Web page/Enforcement Actions, located at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm118712.htm

For more information

Drugs Marketed in the United States That Do Not Have Required FDA Approval

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm

Drugs@FDA - Information on FDA-approved drugs

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

Media Inquiries: Chris Kelly, 301-796-4676, christopher.kelly@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
5. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
9. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
10. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Nev. , May 24, 2016  Diana Russell ... "eats" her organs from the inside out.  This disease ... completely dependent on her children and grandchildren to leave ... her wheelchair, Diana,s family cannot haul the wheelchair.  So ... in the car, and Diana is left to wait ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... First Choice Emergency Room , the ... Tat Nguyen, as the Medical Director of its new DeSoto facility. , “We ... new DeSoto location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching a ... patented refillable hanging wipe dispenser. The campaign kick-off video is located via this link ... 25, 2016. The goal is to raise $1,000 per day for a total of ...
(Date:5/24/2016)... Michigan (PRWEB) , ... May 24, 2016 , ... ... Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified Nurse Midwife ... Grand Valley State University and then went on to complete her masters degree ...
(Date:5/24/2016)... ... 2016 , ... Educational opportunities, and therefore life chances, have ... providing richer opportunities. Recognizing the key role of housing in this system, equity-minded ... choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused policies. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed ... stem cell therapy technology, protocols and patient results as have been achieved with ... a more accessible standard of care for patients worldwide. , As the Medical Advisory ...
Breaking Medicine News(10 mins):